Ovariancancer

mohsen koolivand
mohsen koolivandJAMARAN hospital en University of Medical Sciences
Peresented by:Mohsen Koolivand MSc Clinical Of
Biochemistry
Molecular Mechanism Of Ovarian Cancer
Outline
 Introduction
 Risk factors
 Molecular Origin
The Molecular Of Mechanism
and Molecular Pathways
Guidelines
Introduction
Mohsen Koolivand MSc
Ovarian
Cancer
3–4% of cancer in women
estimated 22,000 new cases
Second most common gynecologic
malignancy
a disease of the postmenopausal
Early stage (I/II) detection has a survival
rate of over 90%
Symptoms are complex and often
misdiagnosed as other diseases
cellular and molecular characteristics,
identifying appropriate
block lymphatic vessels
Types Of Ovarian Tumors
The ovaries contain 3 main kinds of cells:
1. Epithelial
2. Germ cells
3. Stromal cells
Subsequently there are 3 main types of ovarian tumours:
1. Epithelial tumours
2. Germ cell tumours
3. Stromal tumours
Pelvic or abdominal pain
Symptoms
BloatingUrgent need to urinate
Frequent urination
abnormal menstrual cyclesSense of pelvic heaviness Back pain
Vaginal bleeding
Risk Factors
Family
History
Ethnicity Reproducti
on others
Family History
 The strongest risk factor
 A women with a single first-degree relative with ov.Ca has a relative
risk (RR) of approximately 3.6 for developing ov.ca compared with
general population
 The gene can be inherited through either the maternal or paternal
line, but has variable penetrance
Family History
Ethnicity
 Higher in white women
 Higher in north America and northern Europe
 BRCA1 and BRCA2 genes are more common among white women
of Ashkenazi descent
 Incidence of ov.ca is higher in countries with higher in countries with
higher per capita consumption of animal fat
Reproduction factors
 Nulliparous
 First childbirth after age 35 years
 Involuntary infertility
 Late menopause and early menarche
 Pts. With prolonged period or uninterrupted ovulation
Others
 Exogenous hormones :- HRT
 Dietary factors , Diets high in saturated animal fats seem to confer
an increased risk by unknown mechanisms …
# Japanese women who move to the United States have an
increased ovarian cancer risk.
<<<<<<<<<<<<<<<<
Protective Factors
 Multiparity: First pregnancy before age 30
 Oral contraceptives: 5 years of use cuts risk nearly in half
 Tubal ligation
 Hysterectomy
 Bilateral oopherectomy
 Lactation
 Epidemiologic and laboratory evidence suggest a potential role for
retinoids , vitamin D, NSAIDs as preventive agents for ovarian
cancer
 According to International Federation of Gynecology and Obstetrics
(FIGO) Staging of Ovarian Neoplasms :-
 Stage I. Growth limited to the ovaries
Ia —one ovary involved
Ib —both ovaries involved
Ic —Ia or Ib and ovarian surface tumor, ruptured capsule,
malignant ascites, or peritoneal cytology positive for malignant cells
Staging …
Staging …
 Stage II. Extension of the neoplasm from the ovary to the
pelvis
IIa—extension to the uterus or fallopian tube
IIb—extension to other pelvic tissues
IIc—IIa or b and ovarian surface tumor, ruptured capsule, malignant
ascites, or peritoneal cytology positive for malignant cells
Staging …
Staging …
 Stage III. Disease extension to the abdominal cavity
IIIa—abdominal peritoneal surfaces with microscopic metastases
IIIb—tumor metastases < 2 cm in size
IIIc—tumor metastases > 2 cm in size or metastatic disease in the
pelvic, paraaortic, or inguinal lymph nodes
Staging …
Staging …
 Stage IV. Distant metastatic disease
Malignant pleural effusion
Pulmonary parenchymal metastases
Liver or splenic parenchymal metastases (not surface implants)
Metastases to the supraclavicular lymph nodes or skin
Staging …
 molecular origins of cancer, such as ovarian cancer is influenced
by a complex signaling pathway.
 Ovarian cancer is also heterogeneous — multiple genetic and
epigenetic changes are evident in patients with ovarian cancer;
however, how such changes are selected for during tumorigenesis
is not yet clear.
Molecular Origin
Ovariancancer
Ovariancancer
Ovariancancer
Molecular Pathways
Ovarian cancer is also heterogeneous
— multiple genetic and epigenetic
changes are evident in patients with
ovarian cancer; however, how such
changes are selected for during
tumorigenesis is not yet clear.
Several genetic alterations cause of
high genetic instability in ovarian cancer:
Tumors ovariy
Proliferation
Apoptosis
Autophagy
Motility and invasion
Adhesion
Angiogenesis
characteristic
Sparc
SPARC Is a Key Regulator of Proliferation, Apoptosis and In
vasion in Human Ovarian Cancer
Secreted protein acidic and rich in cysteine (SPARC), a calcium-
binding matricellular glycoprotein, is implicated
in the progression of many cancers. investigations show
expression and function of SPARC in ovarian cancer.
PTEN
PTEN activity can also be lost through other
mechanisms such as epigenetic changes or post-
translational modifications or mutation .
BRCA1 and BRCA2
 BRCA1 and BRCA2 suggests that they are involved in two
fundamental cellular processes: DNA damage repair and
transcriptional regulation.
Ovariancancer
Ovariancancer
Tp53
Ovariancancer
KRAS
 RAS proteins are central mediators downstream of growth factor
receptor signaling and therefore are critical for cell proliferation,
survival, and differentiation.
 KRAS mutations are found in approximately 40% of patients with Type
I EOC tumors. In the majority of cases, these mutations are missense
mutations which introduce an amino acid substitution at position 12,
13, or 61. The result of these mutations is constitutive activation of
KRAS signaling pathways.
Ovariancancer
PI3K
 Activation of the PI3K pathway regulates:
 Cell growth
 Cell proliferation
 Cell survival
 The PI3K/Akt/mTOR pathway is frequently deregulated in OC
 The expression levels of both PIK3CA and phosphorylated Akt (pAkt) found to be associated
with decreased survival, and activation of the pathway, as measured by Akt or mTOR
phosphorylation levels
Ovariancancer
Ovariancancer
1 de 37

Recomendados

miRNA Breast Cancer Prognosis -- Ingenuity Systems por
miRNA Breast Cancer Prognosis -- Ingenuity SystemsmiRNA Breast Cancer Prognosis -- Ingenuity Systems
miRNA Breast Cancer Prognosis -- Ingenuity SystemsNatalie Ng
5.3K vistas24 diapositivas
PhD Defense por
PhD DefensePhD Defense
PhD DefenseSyed Sameer, A
766 vistas98 diapositivas
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D... por
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...
Genetics and Genomics in Cancer 2013: How Genomics is Changing Cancer Care, D...Health Sciences North | Horizon Santé Nord
2K vistas28 diapositivas
Molecular Genetics and Cancer Biology por
Molecular Genetics and Cancer BiologyMolecular Genetics and Cancer Biology
Molecular Genetics and Cancer BiologyMeshari Alzahrani
9.3K vistas95 diapositivas
X linked diseases-mitochondrial diseases por
X linked diseases-mitochondrial diseasesX linked diseases-mitochondrial diseases
X linked diseases-mitochondrial diseasesdr_ekbalabohashem
338 vistas68 diapositivas
Introduction cancer genetics and genomics por
Introduction cancer genetics and genomicsIntroduction cancer genetics and genomics
Introduction cancer genetics and genomicsNuria Lopez-Bigas
4.7K vistas49 diapositivas

Más contenido relacionado

La actualidad más candente

Doc seminar cervical cancer por
Doc seminar cervical cancerDoc seminar cervical cancer
Doc seminar cervical cancerDUVASU
6.5K vistas45 diapositivas
Seminario biologia molecular por
Seminario biologia molecular Seminario biologia molecular
Seminario biologia molecular elianatorres34
33 vistas15 diapositivas
Vol 87-no2-article-3 por
Vol 87-no2-article-3Vol 87-no2-article-3
Vol 87-no2-article-3Rakesh Kumar
187 vistas4 diapositivas
Cancer biology senescence & imortalisation por
Cancer biology senescence & imortalisationCancer biology senescence & imortalisation
Cancer biology senescence & imortalisationGaurav Kumar
609 vistas22 diapositivas
Stefano Volinia, miRNA Signature - Breast Cancer, fged_seattle_2013 por
Stefano Volinia, miRNA Signature - Breast Cancer, fged_seattle_2013Stefano Volinia, miRNA Signature - Breast Cancer, fged_seattle_2013
Stefano Volinia, miRNA Signature - Breast Cancer, fged_seattle_2013Functional Genomics Data Society
1.5K vistas16 diapositivas
Molecular profiling of breast cancer por
Molecular profiling of breast cancerMolecular profiling of breast cancer
Molecular profiling of breast cancerHriman Sharma Sarkar
2.4K vistas45 diapositivas

La actualidad más candente(20)

Doc seminar cervical cancer por DUVASU
Doc seminar cervical cancerDoc seminar cervical cancer
Doc seminar cervical cancer
DUVASU6.5K vistas
Seminario biologia molecular por elianatorres34
Seminario biologia molecular Seminario biologia molecular
Seminario biologia molecular
elianatorres3433 vistas
Vol 87-no2-article-3 por Rakesh Kumar
Vol 87-no2-article-3Vol 87-no2-article-3
Vol 87-no2-article-3
Rakesh Kumar187 vistas
Cancer biology senescence & imortalisation por Gaurav Kumar
Cancer biology senescence & imortalisationCancer biology senescence & imortalisation
Cancer biology senescence & imortalisation
Gaurav Kumar609 vistas
Immuno histo chemistry in gyn oncology por Shruthi Shivdas
Immuno histo chemistry in gyn oncologyImmuno histo chemistry in gyn oncology
Immuno histo chemistry in gyn oncology
Shruthi Shivdas176 vistas
Identification of cancer drivers across tumor types por Nuria Lopez-Bigas
Identification of cancer drivers across tumor typesIdentification of cancer drivers across tumor types
Identification of cancer drivers across tumor types
Nuria Lopez-Bigas8.9K vistas
Differences in microRNA expression during tumor development in the transition... por Enrique Moreno Gonzalez
Differences in microRNA expression during tumor development in the transition...Differences in microRNA expression during tumor development in the transition...
Differences in microRNA expression during tumor development in the transition...
Overexpression of primary microRNA 221/222 in acute myeloid leukemia por Enrique Moreno Gonzalez
Overexpression of primary microRNA 221/222 in acute myeloid leukemiaOverexpression of primary microRNA 221/222 in acute myeloid leukemia
Overexpression of primary microRNA 221/222 in acute myeloid leukemia
Patología Molecular Del Cáncer De Mama por lalfaro
Patología Molecular Del Cáncer De MamaPatología Molecular Del Cáncer De Mama
Patología Molecular Del Cáncer De Mama
lalfaro3K vistas
A germline mutation in the brca1 3'utr predicts stage iv breast cancer por David W. Salzman
A germline mutation in the brca1 3'utr predicts stage iv breast cancerA germline mutation in the brca1 3'utr predicts stage iv breast cancer
A germline mutation in the brca1 3'utr predicts stage iv breast cancer
David W. Salzman539 vistas
Carcinogenesis por Mammootty Ik
CarcinogenesisCarcinogenesis
Carcinogenesis
Mammootty Ik73.9K vistas

Similar a Ovariancancer

Ovarian Malignancy ppt por
Ovarian Malignancy  pptOvarian Malignancy  ppt
Ovarian Malignancy pptAbhishek Kothule
553 vistas57 diapositivas
Ovarian cancer.pptx por
Ovarian cancer.pptxOvarian cancer.pptx
Ovarian cancer.pptxKanishka478113
47 vistas61 diapositivas
Ovarian cancer por
Ovarian cancerOvarian cancer
Ovarian cancerZiyad Salih
42.5K vistas57 diapositivas
MANAGEMENT OF EARLY STAGE OVARIAN MALIGNANCY.ppt por
MANAGEMENT OF EARLY STAGE OVARIAN MALIGNANCY.pptMANAGEMENT OF EARLY STAGE OVARIAN MALIGNANCY.ppt
MANAGEMENT OF EARLY STAGE OVARIAN MALIGNANCY.pptAdeniyiAkiseku
6 vistas46 diapositivas
Ovarian Cancer: Symptoms, Diagnosis and BRCA Testing for High Risk Individuals por
Ovarian Cancer: Symptoms, Diagnosis and BRCA Testing for High Risk IndividualsOvarian Cancer: Symptoms, Diagnosis and BRCA Testing for High Risk Individuals
Ovarian Cancer: Symptoms, Diagnosis and BRCA Testing for High Risk IndividualsSibley Memorial Hospital
6.5K vistas26 diapositivas
Ovarian cancer por
Ovarian cancerOvarian cancer
Ovarian cancerUma Chidiebere
76.7K vistas63 diapositivas

Similar a Ovariancancer (20)

Ovarian cancer por Ziyad Salih
Ovarian cancerOvarian cancer
Ovarian cancer
Ziyad Salih42.5K vistas
MANAGEMENT OF EARLY STAGE OVARIAN MALIGNANCY.ppt por AdeniyiAkiseku
MANAGEMENT OF EARLY STAGE OVARIAN MALIGNANCY.pptMANAGEMENT OF EARLY STAGE OVARIAN MALIGNANCY.ppt
MANAGEMENT OF EARLY STAGE OVARIAN MALIGNANCY.ppt
AdeniyiAkiseku6 vistas
Ovarian Cancer: Symptoms, Diagnosis and BRCA Testing for High Risk Individuals por Sibley Memorial Hospital
Ovarian Cancer: Symptoms, Diagnosis and BRCA Testing for High Risk IndividualsOvarian Cancer: Symptoms, Diagnosis and BRCA Testing for High Risk Individuals
Ovarian Cancer: Symptoms, Diagnosis and BRCA Testing for High Risk Individuals
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c... por European School of Oncology
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
Ov ca prevention jeddah por Basalama Ali
Ov ca prevention jeddahOv ca prevention jeddah
Ov ca prevention jeddah
Basalama Ali277 vistas
Fertility Preservation In Cancer Pt Fin (2) por guest7f0a3a
Fertility Preservation In Cancer Pt Fin (2)Fertility Preservation In Cancer Pt Fin (2)
Fertility Preservation In Cancer Pt Fin (2)
guest7f0a3a819 vistas
Fertility Preservation In Cancer Pt Fin (1) por guest7f0a3a
Fertility Preservation In Cancer Pt Fin (1)Fertility Preservation In Cancer Pt Fin (1)
Fertility Preservation In Cancer Pt Fin (1)
guest7f0a3a338 vistas
Fertility Preservation In Cancer Pt Fin por guest7f0a3a
Fertility Preservation In Cancer Pt FinFertility Preservation In Cancer Pt Fin
Fertility Preservation In Cancer Pt Fin
guest7f0a3a539 vistas
Igcs+ankara cancer+and+pregnancy por aykutozcan
Igcs+ankara cancer+and+pregnancyIgcs+ankara cancer+and+pregnancy
Igcs+ankara cancer+and+pregnancy
aykutozcan838 vistas
Breast cancer por Rahil Dalal
Breast cancerBreast cancer
Breast cancer
Rahil Dalal6.1K vistas
Genesilencing in Breast Cancer por Tamil Jothi
Genesilencing in Breast CancerGenesilencing in Breast Cancer
Genesilencing in Breast Cancer
Tamil Jothi270 vistas
Gene silencing in Breast cancer por Santhi Dasari
Gene silencing in Breast cancer Gene silencing in Breast cancer
Gene silencing in Breast cancer
Santhi Dasari406 vistas
Breast carcinoma overview and recent advances in management por Murthy Murthy(Jnv)
Breast carcinoma overview and recent advances in managementBreast carcinoma overview and recent advances in management
Breast carcinoma overview and recent advances in management
Murthy Murthy(Jnv)223 vistas

Último

INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx por
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptxINTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptxABG
121 vistas40 diapositivas
Buccoadhesive drug delivery System.pptx por
Buccoadhesive drug delivery System.pptxBuccoadhesive drug delivery System.pptx
Buccoadhesive drug delivery System.pptxABG
169 vistas43 diapositivas
Vyadhikshmatva.pptx 1.pptx por
Vyadhikshmatva.pptx 1.pptxVyadhikshmatva.pptx 1.pptx
Vyadhikshmatva.pptx 1.pptxAkshay Shetty
57 vistas29 diapositivas
vitamin c.pptx por
vitamin c.pptxvitamin c.pptx
vitamin c.pptxajithkilpart
21 vistas13 diapositivas
The Art of naming drugs.pptx por
The Art of naming drugs.pptxThe Art of naming drugs.pptx
The Art of naming drugs.pptxDanaKarem1
27 vistas48 diapositivas
Trustlife Türkiye - Güncel Platform Yapısı por
Trustlife Türkiye - Güncel Platform YapısıTrustlife Türkiye - Güncel Platform Yapısı
Trustlife Türkiye - Güncel Platform YapısıTrustlife
48 vistas2 diapositivas

Último(20)

INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx por ABG
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptxINTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
ABG121 vistas
Buccoadhesive drug delivery System.pptx por ABG
Buccoadhesive drug delivery System.pptxBuccoadhesive drug delivery System.pptx
Buccoadhesive drug delivery System.pptx
ABG169 vistas
Vyadhikshmatva.pptx 1.pptx por Akshay Shetty
Vyadhikshmatva.pptx 1.pptxVyadhikshmatva.pptx 1.pptx
Vyadhikshmatva.pptx 1.pptx
Akshay Shetty57 vistas
The Art of naming drugs.pptx por DanaKarem1
The Art of naming drugs.pptxThe Art of naming drugs.pptx
The Art of naming drugs.pptx
DanaKarem127 vistas
Trustlife Türkiye - Güncel Platform Yapısı por Trustlife
Trustlife Türkiye - Güncel Platform YapısıTrustlife Türkiye - Güncel Platform Yapısı
Trustlife Türkiye - Güncel Platform Yapısı
Trustlife48 vistas
Calcutta Clinical Course - Allen College of Homoeopathy por Allen College
Calcutta Clinical Course - Allen College of HomoeopathyCalcutta Clinical Course - Allen College of Homoeopathy
Calcutta Clinical Course - Allen College of Homoeopathy
Allen College98 vistas
CHOLESTEROL SYNTHESIS.pptx por SiphyThindwa1
CHOLESTEROL SYNTHESIS.pptxCHOLESTEROL SYNTHESIS.pptx
CHOLESTEROL SYNTHESIS.pptx
SiphyThindwa113 vistas
Adverse Drug Reactions por NAKUL DHORE
Adverse Drug ReactionsAdverse Drug Reactions
Adverse Drug Reactions
NAKUL DHORE23 vistas
ICH AND WHO GUIDELINES FOR VALIDATION OF EQUIPMENTS.pptx por ABG
ICH AND WHO GUIDELINES FOR VALIDATION OF EQUIPMENTS.pptxICH AND WHO GUIDELINES FOR VALIDATION OF EQUIPMENTS.pptx
ICH AND WHO GUIDELINES FOR VALIDATION OF EQUIPMENTS.pptx
ABG69 vistas
communication and nurse patient relationship by Tamanya Samui.pdf por TamanyaSamui1
communication and nurse patient relationship by Tamanya Samui.pdfcommunication and nurse patient relationship by Tamanya Samui.pdf
communication and nurse patient relationship by Tamanya Samui.pdf
TamanyaSamui141 vistas
Gastro-retentive drug delivery systems.pptx por ABG
Gastro-retentive drug delivery systems.pptxGastro-retentive drug delivery systems.pptx
Gastro-retentive drug delivery systems.pptx
ABG238 vistas
Examining Pleural Fluid.pptx por Fareeha Riaz
Examining Pleural Fluid.pptxExamining Pleural Fluid.pptx
Examining Pleural Fluid.pptx
Fareeha Riaz 25 vistas
Extraordinary Far Infrared Technology - Raising Frequencies with far infrared... por corey268189
Extraordinary Far Infrared Technology - Raising Frequencies with far infrared...Extraordinary Far Infrared Technology - Raising Frequencies with far infrared...
Extraordinary Far Infrared Technology - Raising Frequencies with far infrared...
corey26818960 vistas

Ovariancancer

  • 1. Peresented by:Mohsen Koolivand MSc Clinical Of Biochemistry Molecular Mechanism Of Ovarian Cancer
  • 2. Outline  Introduction  Risk factors  Molecular Origin The Molecular Of Mechanism and Molecular Pathways Guidelines
  • 3. Introduction Mohsen Koolivand MSc Ovarian Cancer 3–4% of cancer in women estimated 22,000 new cases Second most common gynecologic malignancy a disease of the postmenopausal Early stage (I/II) detection has a survival rate of over 90% Symptoms are complex and often misdiagnosed as other diseases cellular and molecular characteristics, identifying appropriate block lymphatic vessels
  • 4. Types Of Ovarian Tumors The ovaries contain 3 main kinds of cells: 1. Epithelial 2. Germ cells 3. Stromal cells Subsequently there are 3 main types of ovarian tumours: 1. Epithelial tumours 2. Germ cell tumours 3. Stromal tumours
  • 5. Pelvic or abdominal pain Symptoms BloatingUrgent need to urinate Frequent urination abnormal menstrual cyclesSense of pelvic heaviness Back pain Vaginal bleeding
  • 7. Family History  The strongest risk factor  A women with a single first-degree relative with ov.Ca has a relative risk (RR) of approximately 3.6 for developing ov.ca compared with general population  The gene can be inherited through either the maternal or paternal line, but has variable penetrance
  • 9. Ethnicity  Higher in white women  Higher in north America and northern Europe  BRCA1 and BRCA2 genes are more common among white women of Ashkenazi descent  Incidence of ov.ca is higher in countries with higher in countries with higher per capita consumption of animal fat
  • 10. Reproduction factors  Nulliparous  First childbirth after age 35 years  Involuntary infertility  Late menopause and early menarche  Pts. With prolonged period or uninterrupted ovulation
  • 11. Others  Exogenous hormones :- HRT  Dietary factors , Diets high in saturated animal fats seem to confer an increased risk by unknown mechanisms … # Japanese women who move to the United States have an increased ovarian cancer risk. <<<<<<<<<<<<<<<<
  • 12. Protective Factors  Multiparity: First pregnancy before age 30  Oral contraceptives: 5 years of use cuts risk nearly in half  Tubal ligation  Hysterectomy  Bilateral oopherectomy  Lactation  Epidemiologic and laboratory evidence suggest a potential role for retinoids , vitamin D, NSAIDs as preventive agents for ovarian cancer
  • 13.  According to International Federation of Gynecology and Obstetrics (FIGO) Staging of Ovarian Neoplasms :-  Stage I. Growth limited to the ovaries Ia —one ovary involved Ib —both ovaries involved Ic —Ia or Ib and ovarian surface tumor, ruptured capsule, malignant ascites, or peritoneal cytology positive for malignant cells Staging …
  • 15.  Stage II. Extension of the neoplasm from the ovary to the pelvis IIa—extension to the uterus or fallopian tube IIb—extension to other pelvic tissues IIc—IIa or b and ovarian surface tumor, ruptured capsule, malignant ascites, or peritoneal cytology positive for malignant cells Staging …
  • 17.  Stage III. Disease extension to the abdominal cavity IIIa—abdominal peritoneal surfaces with microscopic metastases IIIb—tumor metastases < 2 cm in size IIIc—tumor metastases > 2 cm in size or metastatic disease in the pelvic, paraaortic, or inguinal lymph nodes Staging …
  • 19.  Stage IV. Distant metastatic disease Malignant pleural effusion Pulmonary parenchymal metastases Liver or splenic parenchymal metastases (not surface implants) Metastases to the supraclavicular lymph nodes or skin Staging …
  • 20.  molecular origins of cancer, such as ovarian cancer is influenced by a complex signaling pathway.  Ovarian cancer is also heterogeneous — multiple genetic and epigenetic changes are evident in patients with ovarian cancer; however, how such changes are selected for during tumorigenesis is not yet clear. Molecular Origin
  • 24. Molecular Pathways Ovarian cancer is also heterogeneous — multiple genetic and epigenetic changes are evident in patients with ovarian cancer; however, how such changes are selected for during tumorigenesis is not yet clear. Several genetic alterations cause of high genetic instability in ovarian cancer:
  • 25. Tumors ovariy Proliferation Apoptosis Autophagy Motility and invasion Adhesion Angiogenesis characteristic
  • 26. Sparc SPARC Is a Key Regulator of Proliferation, Apoptosis and In vasion in Human Ovarian Cancer Secreted protein acidic and rich in cysteine (SPARC), a calcium- binding matricellular glycoprotein, is implicated in the progression of many cancers. investigations show expression and function of SPARC in ovarian cancer.
  • 27. PTEN PTEN activity can also be lost through other mechanisms such as epigenetic changes or post- translational modifications or mutation .
  • 28. BRCA1 and BRCA2  BRCA1 and BRCA2 suggests that they are involved in two fundamental cellular processes: DNA damage repair and transcriptional regulation.
  • 31. Tp53
  • 33. KRAS  RAS proteins are central mediators downstream of growth factor receptor signaling and therefore are critical for cell proliferation, survival, and differentiation.  KRAS mutations are found in approximately 40% of patients with Type I EOC tumors. In the majority of cases, these mutations are missense mutations which introduce an amino acid substitution at position 12, 13, or 61. The result of these mutations is constitutive activation of KRAS signaling pathways.
  • 35. PI3K  Activation of the PI3K pathway regulates:  Cell growth  Cell proliferation  Cell survival  The PI3K/Akt/mTOR pathway is frequently deregulated in OC  The expression levels of both PIK3CA and phosphorylated Akt (pAkt) found to be associated with decreased survival, and activation of the pathway, as measured by Akt or mTOR phosphorylation levels

Notas del editor

  1. The ovaries produce eggs (called ova). They are also the main source of a woman’s female hormones, estrogen and progesterone. Epithelial ovarian tumors Epithelial ovarian tumors are further divided into 3 sub-groups: benign, low malignant potential, and malignant. Benign epithelial tumors These tumors are not cancer. They don’t spread and usually do not lead to serious illness. Tumors of low malignant potential (LMP tumors) These tumors do not clearly appear to be cancer when looked at under the microscope. They are also known as borderline epithelial ovarian cancer. They tend to affect women at a younger age than other ovarian cancers. They grow and spread slowly and are less life-threatening than most ovarian cancers. Malignant epithelial ovarian tumors These are the most common ovarian cancer. When someone says they have ovarian cancer, they usually mean this kind. These cancers can also be divided into different types based on certain features. The information in this document is about the most common kind of ovarian cancer, invasive epithelial ovarian carcinoma. Be sure to ask your doctor what type of ovarian cancer you have. If you need information about low malignant potential tumors, ovarian stromal tumors, or ovarian germ cell tumors, please see our detailed document, Ovarian Cancer.
  2. If the symptoms suggest ovarian cancer, three tests should be performed: a complete pelvic exam, including a rectum and vaginal exam; a vaginal ultrasound; and a CA-125 blood test
  3. بامزه ترین جواب های بچه ها به سوالات بزرگترها